Sputum ADAM8 expression is increased in severe asthma and COPD

Clinical and Experimental Allergy

Volumn 44, Issue 3, 2014, Pages 342-352

  Oreo, K M ^a,b,c,d   Gibson, P G ^a,b,c,d   Simpson, J L ^a,b   Wood, L G ^a,b   Mcdonald, V M ^a,b   Baines, K J ^a,b  

^a HUNTER MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c WOOLCOCK INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADAM PROTEINS; ADRENAL CORTEX HORMONES; ADULT; AGED; ASTHMA; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOPHENOTYPING; LEUKOCYTE COUNT; LEUKOCYTES; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX; SPUTUM; YOUNG ADULT;

EID: 84894230952     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/cea.12223     Document Type: Article

References (52)

1. Masoli M, Fabian D, Holt S, Beasley R, Global Initiative for Asthma P. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004; 59:469-78.
2. To T, Stanojevic S, Moores G et al. Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health 2012; 12:204.
3. Lopez AD, Shibuya K, Rao C et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J 2006; 27:397-412.
4. World Health Organisation. World Health Report Geneva. 2000; Available from: http://www.who.int/whr/2000/en/statistics.htm [Last accessed 10 June 2012].
5. Rabe KF, Adachi M, Lai CK et al. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol 2004; 114:40-7.
6. Antonicelli L, Bucca C, Neri M et al. Asthma severity and medical resource utilisation. Eur Respir J 2004; 23:723-9.
7. Moore WC, Peters SP. Severe asthma: an overview. J Allergy Clin Immunol 2006; 117:487-94; quiz 95.
8. Godard P, Chanez P, Siraudin L, Nicoloyannis N, Duru G. Costs of asthma are correlated with severity: a 1-yr prospective study. Eur Respir J 2002; 19:61-7.
9. Serra-Batlles J, Plaza V, Morejon E, Comella A, Brugues J. Costs of asthma according to the degree of severity. Eur Respir J 1998; 12:1322-6.
10. Chanez P, Wenzel SE, Anderson GP et al. Severe asthma in adults: what are the important questions? J Allergy Clin Immunol 2007; 119:1337-48.
11. Wenzel SE, Schwartz LB, Langmack EL et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999; 160:1001-8.
12. Berry M, Morgan A, Shaw DE et al. Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma. Thorax 2007; 62:1043-9.
13. Hastie AT, Moore WC, Meyers DA et al. Analyses of asthma severity phenotypes and inflammatory proteins in subjects stratified by sputum granulocytes. J Allergy Clin Immunol 2010;125:1028-36. e13.
14. Simpson JL, Scott R, Boyle MJ, Gibson PG. Inflammatory subtypes in asthma: assessment and identification using induced sputum. Respirology 2006; 11:54-61.
15. Carolan BJ, Sutherland ER. Clinical phenotypes of chronic obstructive pulmonary disease and asthma: recent advances. J Allergy Clin Immunol 2013; 131:627-34; quiz 35.
16. Yoshida S, Setoguchi M, Higuchi Y, Akizuki S, Yamamoto S. Molecular cloning of cDNA encoding MS2 antigen, a novel cell surface antigen strongly expressed in murine monocytic lineage. Int Immunol 1990; 2:585-91.
17. Yamamoto S, Higuchi Y, Yoshiyama K et al. ADAM family proteins in the immune system. Immunol Today 1999; 20:278-84.
18. Yoshiyama K, Higuchi Y, Kataoka M, Matsuura K, Yamamoto S. CD156 (human ADAM8): expression, primary amino acid sequence, and gene location. Genomics 1997; 41:56-62.
19. Paulissen G, Rocks N, Gueders MM et al. ADAM-8, a metalloproteinase, drives acute allergen-induced airway inflammation. Eur J Immunol 2011; 41:380-91.
20. King NE, Zimmermann N, Pope SM et al. Expression and regulation of a disintegrin and metalloproteinase (ADAM) 8 in experimental asthma. Am J Respir Cell Mol Biol 2004; 31:257-65.
21. Gomez-Gaviro M, Dominguez-Luis M, Canchado J et al. Expression and regulation of the metalloproteinase ADAM-8 during human neutrophil pathophysiological activation and its catalytic activity on L-selectin shedding. J Immunol 2007;178:8053-63.
22. Dijkstra A, Postma DS, Noordhoek JA et al. Expression of ADAMs ('a disintegrin and metalloprotease') in the human lung. Virchows Arch 2009; 454:441-9.
23. Richens J, Fairclough L, Ghaemmaghami AM, Mahdavi J, Shakib F, Sewell HF. The detection of ADAM8 protein on cells of the human immune system and the demonstration of its expression on peripheral blood B cells, dendritic cells and monocyte subsets. Immunobiology 2007; 212:29-38.
24. Schlomann U, Wildeboer D, Webster A et al. The metalloprotease disintegrin ADAM8. Processing by autocatalysis is required for proteolytic activity and cell adhesion. J Biol Chem 2002; 277:48210-9.
25. Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 2007; 7:678-89.
26. Zarbock A, Rossaint J. Regulating inflammation: ADAM8-a new player in the game. Eur J Immunol 2011; 41:3419-22.
27. Johansson MW, Lye MH, Barthel SR, Duffy AK, Annis DS, Mosher DF. Eosinophils adhere to vascular cell adhesion molecule-1 via podosomes. Am J Respir Cell Mol Biol 2004; 31:413-22.
28. Dominguez-Luis M, Lamana A, Vazquez J et al. The metalloprotease ADAM8 is associated with and regulates the function of the adhesion receptor PSGL-1 through ERM proteins. Eur J Immunol 2011; 41:3436-42.
29. Naus S, Reipschlager S, Wildeboer D et al. Identification of candidate substrates for ectodomain shedding by the metalloprotease-disintegrin ADAM8. Biol Chem 2006; 387:337-46.
30. Naus S, Blanchet MR, Gossens K et al. The metalloprotease-disintegrin ADAM8 is essential for the development of experimental asthma. Am J Respir Crit Care Med 2010; 181:1318-28.
31. Paulissen G, Rocks N, Quesada-Calvo F et al. Expression of ADAMs and their inhibitors in sputum from patients with asthma. Mol Med 2006;12:171-9.
32. Foley SC, Mogas AK, Olivenstein R et al. Increased expression of ADAM33 and ADAM8 with disease progression in asthma. J Allergy Clin Immunol 2007; 119:863-71.
33. American Thoracic Society, European Respiratory Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med 2005;171:912-30.
34. Buist AS. Standardization of spirometry-1987 update. Statement of the American Thoracic Society. Am Rev Respir Dis 1987;136:1285-98.
35. Knudson RJ, Slatin RC, Lebowitz MD, Burrows B. The maximal expiratory flow-volume curve. Normal standards, variability, and effects of age. Am Rev Respir Dis 1976;113:587-600.
36. Gibson PG, Wlodarczyk JW, Hensley MJ et al. Epidemiological association of airway inflammation with asthma symptoms and airway hyperresponsiveness in childhood. Am J Respir Crit Care Med 1998; 158:36-41.
37. Kelly MM, Leigh R, Carruthers S et al. Increased detection of interleukin-5 in sputum by addition of protease inhibitors. Eur Respir J 2001; 18:685-91.
38. Louis R, Shute J, Goldring K et al. The effect of processing on inflammatory markers in induced sputum. Eur Respir J 1999; 13:660-7.
39. Matsuno O, Miyazaki E, Nureki S, Ueno T, Kumamoto T, Higuchi Y. Role of ADAM8 in experimental asthma. Immunol Lett 2006; 102:67-73.
40. Matsuno O, Miyazaki E, Nureki S et al. Elevated soluble ADAM8 in bronchoalveolar lavage fluid in patients with eosinophilic pneumonia. Int Arch Allergy Immunol 2007; 142:285-90.
41. Matsuno O, Ono E, Ueno T et al. Increased serum ADAM8 concentration in patients with drug-induced eosinophilic pneumonia-ADAM8 expression depends on a the allergen route of entry. Respir Med 2010; 104:34-9.
42. Amour A, Knight CG, English WR et al. The enzymatic activity of ADAM8 and ADAM9 is not regulated by TIMPs. FEBS Lett 2002; 524:154-8.
43. Knolle MD, Nakajima T, Hergrueter A et al. Adam8 limits the development of allergic airway inflammation in mice. J Immunol. 2013;190:6434-49.
44. Cotran RS, Kumar V, Collins T, Robbins SL. Robbins pathologic basis of disease. 6th Edn. Philadelphia: W.B. Saunders Company, 1999:1148-51.
45. Lefebvre JS, Levesque T, Picard S et al. Extra domain A of fibronectin primes leukotriene biosynthesis and stimulates neutrophil migration through activation of Toll-like receptor 4. Arthritis Rheum 2011; 63:1527-33.
46. Monteiro AP, Pinheiro CS, Luna-Gomes T et al. Leukotriene B4 mediates neutrophil migration induced by heme. J Immunol 2011;186:6562-7.
47. Blidberg K, Palmberg L, Dahlen B, Lantz AS, Larsson K. Increased neutrophil migration in smokers with or without chronic obstructive pulmonary disease. Respirology 2012; 17:854-60.
48. Afonso PV, Janka-Junttila M, Lee YJ et al. LTB4 is a signal-relay molecule during neutrophil chemotaxis. Dev Cell 2012; 22:1079-91.
49. Uddin M, Nong G, Ward J et al. Prosurvival activity for airway neutrophils in severe asthma. Thorax 2010; 65:684-9.
50. Duncan CJ, Lawrie A, Blaylock MG, Douglas JG, Walsh GM. Reduced eosinophil apoptosis in induced sputum correlates with asthma severity. Eur Respir J 2003; 22:484-90.
51. Porsbjerg C, Lund TK, Pedersen L, Backer V. Inflammatory subtypes in asthma are related to airway hyperresponsiveness to mannitol and exhaled NO. J Asthma 2009; 46:606-12.
52. Brooks CR, Gibson PG, Douwes J, Dalen CJ, Simpson JL. Relationship between airway neutrophilia and ageing in asthmatics and non-asthmatics. Respirology 2013; 18:857-65.